<DOC>
	<DOCNO>NCT01265368</DOCNO>
	<brief_summary>This Phase 1/2 , proof-of-principle clinical study ass safety efficacy intradermally administer tumor vaccine ( MGN1601 ) . The study conduct patient advanced renal cell carcinoma .</brief_summary>
	<brief_title>A Clinical Study Assess Safety Efficacy Tumor Vaccine Patients With Advanced Renal Cell Carcinoma ( ASET )</brief_title>
	<detailed_description>Twenty four patient advanced RCC include open , single-arm study . The treatment last 12 week . The investigational product ( MGN1601 ) administer intradermally total 8 application , whereas first 3 application administered weekly , follow 5 application administer bi-weekly . Patients develop disease control ( CR , PR , SD ) week 12 propose participate extension phase study . The extension phase continue disease progression patient , however , maximally week 120 ( total treatment duration 2.5 year ) . During time period investigational product administer 5 time week 24 , 36 , 48 , 72 , 120 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Immunologic Factors</mesh_term>
	<mesh_term>Adjuvants , Immunologic</mesh_term>
	<criteria>Male female subject older 18 year age Histologically confirm renal cell carcinoma Radiologically confirm advanced disease define unresectable locally reccurrent metastatic disease ( AJCC Stage IV ) Previous nephrectomy No standard therapy available patient At least 4 week previous radiotherapy prior study treatment At least 1 week previous systemic therapy prior study treatment At least one lesion measurable modify RECIST criterion ECOG performance status 01 Adequate organ function include hematopoietic organ MSKCC prognostic ctiteria &lt; 3 predictor short survival Negative urine pregnancy test woman childbearing potential Women childbearing potential male participant willing use acceptable method contraception ( birth control pill , barrier ) Expected adequacy followup Signed informed consent form ( ICF ) . Clinically significant concomitant disease condition unrelated underlying malignancy therapy , opinion investigator would lead unacceptable risk subject participate study Known hypersensitivity component study drug Prior current malignancy , except adequately treat superficial bladder cancer , basal squamous cell carcinoma skin cancer subject disease free 3 year Active brain metastasis except adequately treat brain metastasis progression least 3 month Active uncontrolled infection Transfusiondependent anemia History autoimmune disease immune deficiency Concurrent chronic systemic immune therapy , corticosteroid immunosuppressant medication Concurrent radiotherapy within last 4 week prior study treatment and/or course study Concurrent immunotherapy target therapy within last 1 week prior study treatment and/or course study HIV seropositivity active hepatitis B C infection Planned major surgery study Participation clinical study clinical study Vaccination within 3 month prior first treatment day Any medical , mental , psychological psychiatric condition opinion investigator would permit subject complete study understand patient information Pregnancy and/or nurse Presence drug and/or alcohol abuse Commitment institution virtue order issue either judicial administrative authority .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Advanced Renal Cell Carcinoma</keyword>
	<keyword>Tumor Vaccine</keyword>
	<keyword>Cell-based Therapy</keyword>
</DOC>